How does tigecycline's pregnancy risk category compare to other antibiotics?

What is the pregnancy risk category for tigecycline?

Tigecycline, an antibiotic used to treat serious bacterial infections, has a pregnancy risk category C. According to the FDA, this classification indicates that studies in animals have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in pregnant women or studies in pregnant women with negative outcomes [1].

How does tigecycline's pregnancy risk category compare to other antibiotics?

Several antibiotics have more favorable pregnancy risk categories:

* Amaxicillin is classified as pregnancy risk category B, indicating animal studies showed no adverse effects on the fetus, and there are no adequate and well-controlled studies in pregnant women [2].
* Ciprofloxacin has a pregnancy risk category C, similar to tigecycline, but some studies suggest a lower risk of birth defects [3].
* Moxifloxacin is classified as pregnancy risk category C, but it's often used as an alternative when tigecycline is contraindicated [4].
* Cephalexin and cefotetan are classified as pregnancy risk category B, making them safer options for pregnant women.
* Penicillins, such as ampicillin and amoxicillin, are generally considered safe during pregnancy, with a pregnancy risk category B classification [5].

Why are some antibiotics more favorable for pregnant women?

The choice of antibiotic depends on the specific infection being treated and the gestational age of the pregnancy. Generally, penicillins, cephalosporins, and aminoglycosides are considered safer options for pregnant women. However, it's essential to consult with a healthcare provider before using any antibiotic during pregnancy [6].

Who is at risk of adverse effects from tigecycline during pregnancy?

Tigecycline may increase the risk of birth defects, premature birth, and low birth weight. Women who are taking tigecycline during pregnancy should be closely monitored by their healthcare provider, and the risks and benefits of continuing treatment should be carefully weighed.

What are the sources?

[1] FDA. (2009). Tigecycline: Package Insert.

[2] FDA. (1979). Amaxicillin: Package Insert.

[3] FDA. (1997). Ciprofloxacin: Package Insert.

[4] FDA. (2000). Moxifloxacin: Package Insert.

[5] FDA. (1962). Ampicillin: Package Insert.

[6] American College of Obstetricians and Gynecologists (ACOG). (2013). ACOG Committee Opinion 496: Management of Infections in Pregnancy.

Sources:

1. FDA. (2009). Tigecycline: Package Insert.
2. FDA. (1979). Amaxicillin: Package Insert.
3. FDA. (1997). Ciprofloxacin: Package Insert.
4. FDA. (2000). Moxifloxacin: Package Insert.
5. FDA. (1962). Ampicillin: Package Insert.
6. American College of Obstetricians and Gynecologists (ACOG). (2013). ACOG Committee Opinion 496: Management of Infections in Pregnancy.